Breaking News Instant updates and real-time market news.

2021-01-12 08:11:26 GILD Gilead $62.50 / -0.54 (-0.86%) , VIR Vir Biotechnology $28.30 / +0.46 (+1.65%) 08:11 01/12/21 01/12 08:11 01/12/21 08:11	Gilead, Vir Biotechnology establish collaboration for chronic HBV Gilead Sciences (GILD) and Vir Biotechnology (VIR) announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus. The companies plan to initiate a Phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naive people living with HBV. The multi-arm trial will evaluate different combinations of selgantolimod, Gilead's investigational TLR-8 agonist; VIR-2218, Vir's investigational small interfering ribonucleic acid; and a commercially-sourced, marketed PD-1 antagonist. People in the trial with HBV treatment experience may also receive Gilead's Vemlidy. The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B surface antigen and HBV DNA from the serum. Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial. GILD Gilead $62.50 / -0.54 (-0.86%) VIR Vir Biotechnology $28.30 / +0.46 (+1.65%)	08 Jul
GILD VIR GILD Gilead $62.50 / -0.54 (-0.86%) 01/11/21 Piper Sandler Piper says hard for Gilead investors to ascribe long-term value to Veklury 01/04/21 Guggenheim Gilead upgraded to Buy from Neutral at Guggenheim 12/22/20 Citi Gilead price target lowered to $72 from $75 at Citi 12/18/20 Truist Gilead price target lowered to $62 from $67 at Truist VIR Vir Biotechnology $28.30 / +0.46 (+1.65%) 12/24/20 Baird Baird maintains 'profound skepticism' of Vir's COVID antibody after Lilly data 10/07/20 Goldman Sachs Goldman says Lilly comments support need for multiple COVID-19 antibody makers 10/07/20 H.C. Wainwright Vir Biotechnology price target raised to $100 from $80 at H.C. Wainwright 10/05/20 Fly Intel: Top five analyst initiations

2021-01-12 08:11:26

GILD

Gilead

$62.50 / -0.54 (-0.86%)

, VIR

Vir Biotechnology

$28.30 / +0.46 (+1.65%)

08:11

01/12/21

01/12

08:11

01/12/21

08:11

Gilead, Vir Biotechnology establish collaboration for chronic HBV

Gilead Sciences (GILD) and Vir Biotechnology (VIR) announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus. The companies plan to initiate a Phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naive people living with HBV. The multi-arm trial will evaluate different combinations of selgantolimod, Gilead's investigational TLR-8 agonist; VIR-2218, Vir's investigational small interfering ribonucleic acid; and a commercially-sourced, marketed PD-1 antagonist. People in the trial with HBV treatment experience may also receive Gilead's Vemlidy. The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B surface antigen and HBV DNA from the serum. Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial.

GILD

Gilead

$62.50 / -0.54 (-0.86%)

VIR

Vir Biotechnology

$28.30 / +0.46 (+1.65%)

08
Jul

GILD
VIR

GILD Gilead

$62.50 / -0.54 (-0.86%)

01/11/21 Piper Sandler: Piper says hard for Gilead investors to ascribe long-term value to Veklury

01/04/21 Guggenheim: Gilead upgraded to Buy from Neutral at Guggenheim

12/22/20 Citi: Gilead price target lowered to $72 from $75 at Citi

12/18/20 Truist: Gilead price target lowered to $62 from $67 at Truist

VIR Vir Biotechnology

$28.30 / +0.46 (+1.65%)

12/24/20 Baird: Baird maintains 'profound skepticism' of Vir's COVID antibody after Lilly data

10/07/20 Goldman Sachs: Goldman says Lilly comments support need for multiple COVID-19 antibody makers

10/07/20 H.C. Wainwright: Vir Biotechnology price target raised to $100 from $80 at H.C. Wainwright

10/05/20: Fly Intel: Top five analyst initiations

TODAY'S FREE FLY STORIES

Downgrade	Taiheiyo Cement downgraded to Neutral from Buy at Mizuho » 05:22 02/25/21 02/25 05:22 02/25/21 05:22 THYCY Taiheiyo Cement $0.00 / + (+0.00%) Mizuho analyst Hiroshi… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Upgrade	Nike upgraded to Buy from Hold at HSBC » 05:22 02/25/21 02/25 05:22 02/25/21 05:22 NKE Nike $135.79 / -0.35 (-0.26%) HSBC analyst Erwan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options NKE Nike $135.79 / -0.35 (-0.26%) 02/16/21 Third Point buys Upstart, exits Caesars in Q4 02/01/21 Nike announces Nike GO FlyEase hands-free shoe 01/27/21 Columbia Sportswear names Skip Potter as Chief Digital Information Officer 12/18/20 Nike says experienced 80% growth in Nike digital this quarter NKE Nike $135.79 / -0.35 (-0.26%) 02/05/21 Citi Foot Locker upgraded to Buy from Neutral at Citi 02/05/21 Citi Citi sees 'many reasons' for why Nike should acquire Foot Locker 02/03/21 Jefferies Under Armour price target raised to $25 from $23 at Jefferies 01/25/21 KeyBanc Nike price target raised to $180 from $174 at KeyBanc NKE Nike $135.79 / -0.35 (-0.26%) 12/18/20 Nike raises FY21 revenue growth view to low teens 12/18/20 Nike reports Q2 inventories $6.1B, down 2% 12/18/20 Nike reports Q2 NIKE Brand revenue $10.7B, up 8% 12/18/20 Nike reports Q2 NIKE Direct sales $4.3B, up 32% NKE Nike $135.79 / -0.35 (-0.26%) 12/02/20 UPS imposes shipping restrictions on Gap, Nike, WSJ reports NKE Nike $135.79 / -0.35 (-0.26%) 02/09/21 Fly Intel: What to watch in Under Armour earnings report 02/05/21 Citi says buy Foot Locker, sees 'many reasons' why Nike should too 12/21/20 Fly Intel: Wall Street's top stories for Monday 12/21/20 Fly Intel: Wall Street's top stories at midday 03/18/21 Nike - NKE NKE Nike $135.79 / -0.35 (-0.26%) 12/21/20 Early notable gainers among liquid option names on December 21st 12/18/20 Nike options imply 8.7% move in share price post-earnings 11/10/20 Nike call volume above normal and directionally bullish 09/24/20 Unusually active option classes on open September 24th
Earnings	NetEase reports Q4 EPS 36c, consensus 45c » 05:21 02/25/21 02/25 05:21 02/25/21 05:21 NTES NetEase $117.62 / -2.69 (-2.24%) Reports Q4 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options NTES NetEase $117.62 / -2.69 (-2.24%) 09/18/20 NetEase announces ADS ratio change of five-for-one 09/16/20 NetEase Cloud Music enters strategic partnership with BMG 09/02/20 India bans 118 Chinese mobile apps, including Alipay and Baidu NTES NetEase $117.62 / -2.69 (-2.24%) 02/16/21 Barclays NetEase price target raised to $155 from $110 at Barclays 12/31/20 NetEase initiated with an Outperform at Industrial Securities 11/02/20 Goldman Sachs NetEase price target raised to $107 from $104 at Goldman Sachs 10/07/20 Citi NetEase price target lowered to $106 from $112.60 at Citi NTES NetEase $117.62 / -2.69 (-2.24%) 02/24/21 Notable companies reporting before tomorrow's open 02/24/21 Notable companies reporting before tomorrow's open 11/19/20 NetEase reports Q3 adj. EPS 64c, consensus 39c NTES NetEase $117.62 / -2.69 (-2.24%) 12/12/20 Delisting Chinese companies bad for investors, right thing to do, Barron's says NTES NetEase $117.62 / -2.69 (-2.24%) 11/19/20 Fly Intel: Pre-market Movers 07:00 Today NetEase - NTES NTES NetEase $117.62 / -2.69 (-2.24%) 01/11/21 NetEase put volume heavy and directionally bearish 12/02/20 NetEase put volume heavy and directionally bearish 10/05/20 Notable open interest changes for October 5th
Upgrade	Dixons Carphone upgraded to Buy from Hold at Investec » 05:21 02/25/21 02/25 05:21 02/25/21 05:21 DSITF Dixons Carphone $0.00 / + (+0.00%) Investec analyst Benedict… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research DSITF Dixons Carphone $0.00 / + (+0.00%) 01/18/21 RBC Capital Dixons Carphone upgraded to Outperform from Sector Perform at RBC Capital 12/17/20 Barclays Dixons Carphone price target raised to 145 GBp from 120 GBp at Barclays 10/16/20 RBC Capital Dixons Carphone upgraded to Sector Perform from Underperform at RBC Capital 09/04/20 Exane BNP Paribas Dixons Carphone downgraded to Neutral from Outperform at Exane BNP Paribas
Upgrade	NXP Semiconductors upgraded to Buy from Neutral at Citi » 05:19 02/25/21 02/25 05:19 02/25/21 05:19 NXPI NXP Semiconductors $186.31 / +5.27 (+2.91%) Citi analyst Christopher… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options NXPI NXP Semiconductors $186.31 / +5.27 (+2.91%) 02/17/21 NXP Semiconductors idles manufacturing at two Austin facilities 02/12/21 NXP Semiconductors' Wuamett sells 2,697 common shares 02/03/21 NXP Semiconductors announces EdgeLock 2GO IoT services platform 12/09/20 NXP Semiconductors' Owen sells over 7,000 common shares NXPI NXP Semiconductors $186.31 / +5.27 (+2.91%) 02/17/21 Wells Fargo Wells says NXP plants in Austin make up less than 30% of production sq. footage 02/03/21 Fly Intel: Top five analyst upgrades 02/03/21 NXP Semiconductors price target raised to $223 from $200 at Needham 02/03/21 Credit Suisse NXP Semiconductors price target raised to $215 from $175 at Credit Suisse NXPI NXP Semiconductors $186.31 / +5.27 (+2.91%) 02/01/21 NXP Semiconductors sees Q1 revenue $2.48B-$2.55B, consensus $2.31B 02/01/21 NXP Semiconductors reports Q4 EPS $1.08, consensus $2.10 10/26/20 NXP Semiconductors reports Q3 EPS (8c) vs. 38c a year ago 10/26/20 NXP Semiconductors sees Q4 adjusted operating income $692M-$766M NXPI NXP Semiconductors $186.31 / +5.27 (+2.91%) 02/17/21 Samsung, NXP, Infineon have power shut off in Austin, AAS reports NXPI NXP Semiconductors $186.31 / +5.27 (+2.91%) 02/01/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 12/15/20 Wells Fargo upgrade, Dick's Sporting initiation among top calls on Wall Street 10/26/20 Fly Intel: After-Hours Movers NXPI NXP Semiconductors $186.31 / +5.27 (+2.91%) 02/01/21 NXP Semiconductors options imply 8.7% move in share price post-earnings 10/01/20 NXP Semiconductors put volume heavy and directionally bearish 09/08/20 NXP Semiconductors put volume heavy and directionally bearish 09/04/20 NXP Semiconductors put volume heavy and directionally bearish

Earnings	Youdao reports Q4 EPS (58c), consensus (70c) » 05:18 02/25/21 02/25 05:18 02/25/21 05:18 DAO Youdao $30.20 / +0.695 (+2.36%) Reports Q4 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events Options DAO Youdao $30.20 / +0.695 (+2.36%) 02/10/21 Youdao falls -15.2% 11/19/20 Youdao rises 14.4% DAO Youdao $30.20 / +0.695 (+2.36%) 01/04/21 Macquarie Youdao initiated with an Outperform at Macquarie 01/04/21 Macquarie Youdao initiated with an Outperform at Macquarie 10/22/20 Nomura Nomura downgrades GSX Techedu to Reduce, cuts target to 'Street-low' $38 09/02/20 Fly Intel: Top five analyst downgrades DAO Youdao $30.20 / +0.695 (+2.36%) 11/19/20 Youdao reports Q3 EPS ($1.12), two estimates ($1.18) 11 Feb 06:00 Today Youdao - DAO DAO Youdao $30.20 / +0.695 (+2.36%) 10/28/20 Seven new option listings on October 28th
Upgrade	Suzuki Motor upgraded to Outperform from Neutral at Daiwa » 05:18 02/25/21 02/25 05:18 02/25/21 05:18 SZKMY Suzuki Motor $0.00 / + (+0.00%) Daiwa analyst Eiji… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research SZKMY Suzuki Motor $0.00 / + (+0.00%) 10/03/20 Goldman Sachs Suzuki Motor upgraded to Conviction Buy from Buy at Goldman Sachs 08/28/20 Daiwa Suzuki Motor downgraded to Neutral from Outperform at Daiwa 03/17/20 Nomura Instinet Suzuki Motor upgraded to Neutral from Reduce at Nomura Instinet
Downgrade	Solon Eiendom downgraded to Hold from Buy at DNB Markets » 05:17 02/25/21 02/25 05:17 02/25/21 05:17 BNRPF Solon Eiendom $0.00 / + (+0.00%) DNB Markets analyst Simen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Downgrade	Scor downgraded to Hold from Buy at Commerzbank » 05:16 02/25/21 02/25 05:16 02/25/21 05:16 SCRYY Scor $0.00 / + (+0.00%) Commerzbank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research SCRYY Scor $0.00 / + (+0.00%) 01/12/21 Berenberg Scor price target raised to EUR 36 from EUR 32 at Berenberg 12/17/20 Bryan Garnier Scor downgraded to Buy from Conviction Buy at Bryan Garnier 11/30/20 Morgan Stanley Scor price target raised to EUR 36 from EUR 33 at Morgan Stanley 11/18/20 RBC Capital Scor upgraded to Outperform from Sector Perform at RBC Capital
Upgrade	GB Group upgraded to Buy from Hold at Stifel » 05:15 02/25/21 02/25 05:15 02/25/21 05:15 GBGPF GB Group $0.00 / + (+0.00%) Stifel analyst Bridie… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research GBGPF GB Group $0.00 / + (+0.00%) 10/29/20 Panmure Gordon GB Group upgraded to Buy from Hold at Panmure Gordon 10/20/20 Berenberg GB Group upgraded to Buy from Hold at Berenberg 10/12/20 Citi Citi opens 'positive catalyst watch' on GB Group 10/07/20 Canaccord GB Group upgraded to Buy from Hold at Canaccord

Upgrade	JCR Pharmaceuticals upgraded to Outperform from Neutral at Credit Suisse » 05:14 02/25/21 02/25 05:14 02/25/21 05:14 JCRRF JCR Pharmaceuticals $0.00 / + (+0.00%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Hot Stocks	TD Holdings subsidiary granted Dangerous Chemicals Business License » 05:14 02/25/21 02/25 05:14 02/25/21 05:14 GLG TD Holdings $2.44 / +0.14 (+6.09%) TD Holdings announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News GLG TD Holdings $2.44 / +0.14 (+6.09%) 02/17/21 TD Holdings signs LOI to acquire digital cloud warehouse software copyrights 12/15/20 TD Holdings enters LOI to acquire Tongdow 12/04/20 TD Holdings issues statement on recent stock volatility
Upgrade	Vestas upgraded to Buy from Neutral at UBS » 05:13 02/25/21 02/25 05:13 02/25/21 05:13 VWDRY Vestas $0.00 / + (+0.00%) UBS analyst Supriya… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research VWDRY Vestas $0.00 / + (+0.00%) 02/11/21 Deutsche Bank Vestas price target lowered to DKK 1,460 from DKK 1,500 at Deutsche Bank 02/08/21 Deutsche Bank Vestas price target lowered to DKK 1,500 from DKK 1,630 at Deutsche Bank 02/08/21 SEB Equities Vestas downgraded to Hold from Buy at SEB Equities 01/15/21 Morgan Stanley Vestas price target raised to DKK 1,099 from DKK 1,066 at Morgan Stanley
Hot Stocks	Xencor, UCLA TDG collaborate to develop XmAb therapeutics » 05:12 02/25/21 02/25 05:12 02/25/21 05:12 XNCR Xencor $48.58 / +0.09 (+0.19%) Xencor and UCLA… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings XNCR Xencor $48.58 / +0.09 (+0.19%) 02/23/21 Xencor expects to have cash to fund operations into 2024 01/06/21 Xencor, MD Anderson collaborate to develop antibodies for cancer treatment 12/17/20 Miragen Therapeutics enters license agreement with Xencor for Xtend technology 12/07/20 Xencor in pact with Janssen to discover antibodies to treat prostate cancer XNCR Xencor $48.58 / +0.09 (+0.19%) 02/24/21 Piper Sandler Xencor remains a top pick for 2021 at Piper Sandler 02/24/21 RBC Capital Xencor price target raised to $59 from $48 at RBC Capital 02/24/21 Raymond James Xencor upgraded to Outperform from Market Perform at Raymond James 02/24/21 Barclays Xencor price target raised to $34 from $31 at Barclays XNCR Xencor $48.58 / +0.09 (+0.19%) 02/23/21 Xencor reports Q4 EPS (24c), consensus (38c) 11/05/20 Xencor reports Q3 EPS (22c), consensus (23c)
Upgrade	AstraZeneca upgraded to Buy from Neutral at UBS » 05:11 02/25/21 02/25 05:11 02/25/21 05:11 AZN AstraZeneca $49.17 / +0.81 (+1.67%) UBS analyst Michael… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AZN AstraZeneca $49.17 / +0.81 (+1.67%) 02/24/21 ChemoCentryx appoints Tausif Butt as EVP, COO 02/22/21 House committee posts remarks from Pfizer, Moderna, J&J execs ahead of testimony 02/22/21 AstraZeneca notes U.S. withdrawal of Imfinzi advanced bladder cancer indication 02/18/21 AstraZeneca's Covid vaccine granted approval in Nigeria for emergency use AZN AstraZeneca $49.17 / +0.81 (+1.67%) 02/04/21 Piper Sandler Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler 02/01/21 BofA BofA downgrades Moderna to Underperform, sees shares priced for 'best-case' 01/22/21 Barclays AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays 01/19/21 BTIG Adaptive Biotechnologies price target raised to $74 from $66 at BTIG AZN AstraZeneca $49.17 / +0.81 (+1.67%) 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year AZN AstraZeneca $49.17 / +0.81 (+1.67%) 02/24/21 Germany to receive 16M AstraZeneca Covid vaccines in Q2, Reuters reports 02/23/21 AstraZeneca: COVID-19 vaccine could receive U.S. EUA by April, Reuters says 02/23/21 AstraZeneca sees missing EU vaccine supply target in Q2, Reuters reports 02/16/21 South Africa to share AstraZeneca COVID-19 vaccine doses, Reuters reports AZN AstraZeneca $49.17 / +0.81 (+1.67%) 02/16/21 Fly Intel: Wall Street's top stories for Tuesday 02/16/21 Fly Intel: Wall Street's top stories at midday 02/08/21 Fly Intel: Wall Street's top stories for Monday 02/08/21 Fly Intel: Wall Street's top stories at midday 02/27/21 AAAAI Virtual Annual Meeting 2021 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 03/20/21 PDUFA Date for Roxadustat--Extended Date 05/06/21 FARXIGA Granted Priority Review for Chronic Kidney Disease AZN AstraZeneca $49.17 / +0.81 (+1.67%) 02/24/21 AstraZeneca call volume above normal and directionally bullish 02/17/21 AstraZeneca call volume above normal and directionally bullish 12/30/20 Unusually active option classes on open December 30th 12/29/20 Unusually active option classes on open December 29th

General news	FX Action: USD-CAD has posted a three-year low » 05:10 02/25/21 02/25 05:10 02/25/21 05:10 FX Action: USD-CAD has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Earnings	Vipshop reports Q4 EPS 54c, consensus 49c » 05:07 02/25/21 02/25 05:07 02/25/21 05:07 VIPS Vipshop $36.39 / -0.07 (-0.19%) Reports Q4 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options VIPS Vipshop $36.39 / -0.07 (-0.19%) 11/12/20 Vipshop rises 6.6% 11/02/20 Vipshop appoints Pengjun Lu as co-CTO 10/19/20 Vipshop appoints David Cui as new CFO VIPS Vipshop $36.39 / -0.07 (-0.19%) 02/01/21 Morgan Stanley Vipshop user engagement to underpin 'solid' user growth, says Morgan Stanley 02/01/21 Morgan Stanley Vipshop upgraded to Overweight from Underweight at Morgan Stanley 01/26/21 KeyBanc Vipshop downgraded to Sector Weight at KeyBanc on lack of drivers 01/26/21 KeyBanc Vipshop downgraded to Sector Weight from Overweight at KeyBanc VIPS Vipshop $36.39 / -0.07 (-0.19%) 11/13/20 Vipshop reports Q3 EPS 27c, consensus 26c VIPS Vipshop $36.39 / -0.07 (-0.19%) 12/30/20 China fines Alibaba, JD.com, Vipshop for mispricing products, WSJ reports VIPS Vipshop $36.39 / -0.07 (-0.19%) 11/16/20 Verizon resumption, Tapestry upgrade among today's top calls on Wall Street 09/28/20 Fly Intel: Wall Street's top stories for Monday 09/28/20 Fly Intel: Wall Street's top stories at midday 09/28/20 Fly Intel: Pre-market Movers 07:30 Today Vipshop - VIPS VIPS Vipshop $36.39 / -0.07 (-0.19%) 02/23/21 Vipshop call volume above normal and directionally bullish 02/03/21 Vipshop call volume above normal and directionally bullish 02/01/21 Vipshop call volume above normal and directionally bullish 01/13/21 Vipshop put volume heavy and directionally bearish
Recommendations	Elastic price target raised to $185 from $175 at Jefferies » 05:05 02/25/21 02/25 05:05 02/25/21 05:05 ESTC Elastic $157.48 / +4.36 (+2.85%) Jefferies analyst Brent… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly ESTC Elastic $157.48 / +4.36 (+2.85%) 01/05/21 Elastic appoints Ashutosh Kulkarni as chief product officer 12/03/20 Elastic rises 16.2% 12/03/20 Elastic rises 9.4% 12/02/20 Elastic introduces Elastic Cloud on Amazon Web Services ESTC Elastic $157.48 / +4.36 (+2.85%) 02/19/21 RBC Capital Elastic price target raised to $175 from $155 at RBC Capital 01/21/21 Goldman Sachs Elastic initiated with a Neutral at Goldman Sachs 01/19/21 Truist Elastic initiated with a Buy at Truist 01/15/21 Stifel Elastic upgraded to Buy after licensing changes at Stifel ESTC Elastic $157.48 / +4.36 (+2.85%) 02/24/21 Elastic sees FY21 EPS (19c) to (16c), consensus (33c) 02/24/21 Elastic sees Q4 EPS (18c) to (15c), consensus (22c) 02/24/21 Elastic reports Q3 EPS (4c), consensus (15c) 12/02/20 Elastic raises FY21 adj. EPS view to (40c)-(32c) from (83c)-(69c) ESTC Elastic $157.48 / +4.36 (+2.85%) 02/24/21 Fly Intel: After-Hours Movers 01/13/21 Citi says sell Palantir on deceleration in growth, upcoming lockup expiry 12/02/20 Fly Intel: After-Hours Movers 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever
Upgrade	National Bank of Canada upgraded to Outperform from Market Perform at BMO » 05:03 02/25/21 02/25 05:03 02/25/21 05:03 NTIOF National Bank of Canada $0.00 / + (+0.00%) BMO Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research NTIOF National Bank of Canada $0.00 / + (+0.00%) 02/17/21 Scotiabank National Bank of Canada price target raised to C$89 from C$88 at Scotiabank 02/16/21 Barclays National Bank of Canada price target raised to C$81 from C$78 at Barclays 12/03/20 TD Securities National Bank of Canada price target raised to C$79 from C$78 at TD Securities 12/03/20 BMO Capital National Bank of Canada price target raised to C$77 from C$72 at BMO Capital
Recommendations	Vapotherm price target lowered to $36 from $39 at Piper Sandler » 05:01 02/25/21 02/25 05:01 02/25/21 05:01 VAPO Vapotherm $26.99 / -0.42 (-1.53%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options VAPO Vapotherm $26.99 / -0.42 (-1.53%) 02/12/21 Vapotherm's HVT2.0 added to FDA's ventilator accessories EUA 11/09/20 Vapotherm falls -24.0% VAPO Vapotherm $26.99 / -0.42 (-1.53%) 01/15/21 Piper Sandler Vapotherm price target raised to $39 from $36 at Piper Sandler 01/13/21 Piper Sandler Vapotherm remains top small pick at Piper Sandler 12/17/20 Fly Intel: Top five analyst initiations 12/17/20 Piper Sandler Vapotherm initiated with an Overweight at Piper Sandler VAPO Vapotherm $26.99 / -0.42 (-1.53%) 02/24/21 Vapotherm sees FY21 revenue $82M-$88M, consensus $89.76M 02/24/21 Vapotherm sees Q1 revenue $30M-$33M , consensus $24.26M 02/24/21 Vapotherm reports Q4 EPS (67c), consensus (54c) 01/13/21 Vapotherm sees FY20 revenue approximately $125.4M, consensus $117.06M 07 May VAPO Vapotherm $26.99 / -0.42 (-1.53%) 12/01/20 Fly Intel: After-Hours Movers VAPO Vapotherm $26.99 / -0.42 (-1.53%) 11/04/20 Vapotherm options imply 25.3% move in share price post-earnings

Recommendations	Redfin price target raised to $99 from $73 at Piper Sandler » 05:00 02/25/21 02/25 05:00 02/25/21 05:00 RDFN Redfin $91.61 / +0.95 (+1.05%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options RDFN Redfin $91.61 / +0.95 (+1.05%) 02/19/21 Redfin enters agreement to acquire RentPath for $608M in cash 01/06/21 Redfin expands RedfinNow to Phoenix 10/13/20 Redfin reports U.S. luxury home sales increased 41.5% in Q3 09/11/20 Redfin says U.S. median home sale prices up 13% from last year RDFN Redfin $91.61 / +0.95 (+1.05%) 02/23/21 Truist Redfin price target raised to $102 from $84 at Truist 02/19/21 Piper Sandler Redfin purchase of RentPath 'strategically compelling,' says Piper Sandler 02/05/21 Goldman Sachs Redfin upgraded to Neutral from Sell at Goldman Sachs 01/20/21 DA Davidson Redfin downgraded to Neutral from Buy at DA Davidson RDFN Redfin $91.61 / +0.95 (+1.05%) 02/24/21 Redfin sees Q1 revenue $249M-$255M, consensus $231.79M 02/24/21 Redfin reports Q4 EPS 11c, consensus 4c 02/24/21 Notable companies reporting after market close 11/06/20 Redfin reported Q3 EPS 30c, consensus 25c RDFN Redfin $91.61 / +0.95 (+1.05%) 02/24/21 Fly Intel: After-Hours Movers 02/05/21 Peloton downgrade among today's top calls on Wall Street 01/12/21 NIO downgrade, Wells Fargo upgrade among today's top calls on Wall Street 12/21/20 Microsoft, Walmart upgrades among today's top calls on Wall Street 03/04/21 Real Estate Technology Virtual Conference RDFN Redfin $91.61 / +0.95 (+1.05%) 12/28/20 Redfin put volume heavy and directionally bearish 12/09/20 Redfin call volume above normal and directionally bullish 10/15/20 Redfin put volume heavy and directionally bearish 09/24/20 Redfin put volume heavy and directionally bearish
Recommendations	Booking Holdings price target raised to $2,345 from $1,709 at Piper Sandler » 04:59 02/25/21 02/25 04:59 02/25/21 04:59 BKNG Booking Holdings $2,431.90 / +69.05 (+2.92%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options BKNG Booking Holdings $2,431.90 / +69.05 (+2.92%) 02/24/21 Booking Holdings CEO says 'more confident than ever' in eventual travel recovery 02/16/21 Lone Pine bought Snap and Carvana during Q4, exited PayPal 11/16/20 Lone Pine buys Square, exits Visa in Q3 10/14/20 Eightfold.ai to modernize Booking.com's global talent acquisition processes BKNG Booking Holdings $2,431.90 / +69.05 (+2.92%) 02/22/21 Credit Suisse Booking Holdings price target raised to $2,430 from $2,170 at Credit Suisse 02/18/21 Deutsche Bank Booking Holdings price target raised to $2,680 from $2,585 at Deutsche Bank 01/28/21 Wells Fargo Booking Holdings price target raised to $2,250 from $1,800 at Wells Fargo 01/21/21 Truist Booking Holdings price target raised to $2480 from $2120 at Truist BKNG Booking Holdings $2,431.90 / +69.05 (+2.92%) 02/24/21 Booking Holdings reports Q4 adjusted EPS (57c), consensus ($4.28) 02/24/21 Notable companies reporting after market close 11/05/20 Booking CEO says COVID-19 surge to impact travel in near-term 11/05/20 Booking Holdings reports Q3 adjusted EPS $12.27, consensus $14.13 BKNG Booking Holdings $2,431.90 / +69.05 (+2.92%) 09/29/20 Amazon gets into virtual tourism, with Amazon Explore, GeekWire reports BKNG Booking Holdings $2,431.90 / +69.05 (+2.92%) 01/04/21 Airbnb under pressure as Wall Street analysts roll out coverage following IPO 12/14/20 Disney, Airbnb downgrades among today's top calls on Wall Street 12/10/20 Tesla downgrade, Disney initiation among today's top calls on Wall Street 12/01/20 Pinterest, FedEx upgrades among today's top calls on Wall Street BKNG Booking Holdings $2,431.90 / +69.05 (+2.92%) 01/04/21 Booking Holdings put volume heavy and directionally bearish 09/03/20 Booking Holdings put volume heavy and directionally bearish
Downgrade	Chuy's downgraded to Market Perform from Outperform at BMO Capital » 04:56 02/25/21 02/25 04:56 02/25/21 04:56 CHUY Chuy's $43.99 / +1.58 (+3.73%) BMO Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings Events CHUY Chuy's $43.99 / +1.58 (+3.73%) 02/10/21 Raymond James Chuy's downgraded to Market Perform at Raymond James on valuation 02/10/21 Raymond James Chuy's downgraded to Market Perform from Outperform at Raymond James 01/15/21 Stifel Chuy's upgraded to Buy from Hold at Stifel 11/16/20 BMO Capital Chuy's upgraded to Outperform from Market Perform at BMO Capital CHUY Chuy's $43.99 / +1.58 (+3.73%) 11/05/20 Chuy's not providing FY20 guidance 11/05/20 Chuy's reports Q3 EPS 31c, consensus 12c 03/04/21 Chuy's - CHUY
Initiation	I-MAB initiated with an Overweight at Piper Sandler » 04:55 02/25/21 02/25 04:55 02/25/21 04:55 IMAB I-MAB $57.93 / +0.58 (+1.01%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate On The Fly IMAB I-MAB $57.93 / +0.58 (+1.01%) 02/10/21 I-MAB's Phase 1 study of cancer candidate cleared by China's NMPA 02/05/21 I-Mab reports clinical advancements of antibody uliledlimab in China and U.S. 02/04/21 I-MAB says first patient dosed in Phase 2 clinical study of TJ107 01/25/21 I-MAB, MorphoSys dose first patient in Phase 1 study of TJ210/MOR210 in cancer IMAB I-MAB $57.93 / +0.58 (+1.01%) 12/07/20 H.C. Wainwright I-MAB initiated with a Buy at H.C. Wainwright 09/08/20 Cantor Fitzgerald I-MAB price target raised to $55 from $50 at Cantor Fitzgerald 07/27/20 Cantor Fitzgerald I-MAB initiated with an Overweight at Cantor Fitzgerald 09 Feb 13 Jan IMAB I-MAB $57.93 / +0.58 (+1.01%) 09/04/20 Fly Intel: Wall Street's top stories for Friday 09/04/20 Fly Intel: Wall Street's top stories at midday
Conference/Events	Twitter to host virtual analyst day » 04:55 02/25/21 02/25 04:55 02/25/21 04:55 TWTR Twitter $71.91 / -1.27 (-1.74%) Virtual Analyst Day to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 6 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options TWTR Twitter $71.91 / -1.27 (-1.74%) 02/21/21 Fly Intel: Top five weekend stock stories 02/16/21 Appaloosa buys Macy's and Kohl's, exits AT&T in Q4 02/12/21 Twitter CEO, Jay-Z partner to establish bitcoin development fund 02/10/21 Twitter CFO to CNBC's 'Squawk Box': Company has studied using bitcoin TWTR Twitter $71.91 / -1.27 (-1.74%) 02/22/21 Baird Twitter price target raised to $75 from $65 at Baird 02/18/21 JPMorgan JPMorgan still prefers Twitter to Snap into analyst days next week 02/16/21 Loop Capital Twitter price target raised to $95 from $56 at Loop Capital 02/11/21 Fly Intel: Top five analyst upgrades TWTR Twitter $71.91 / -1.27 (-1.74%) 02/09/21 Twitter sees Q1 revenue $940M-$1.04B, consensus $965.14M 02/09/21 Twitter reports Q4 adjusted EPS 38c, consensus 31c 02/09/21 Notable companies reporting after market close 10/29/20 Twitter reports Q3 adjusted EPS 19c, consensus 6c TWTR Twitter $71.91 / -1.27 (-1.74%) 02/22/21 Twitter held talks to acquire social media startup ShareChat, TechCrunch reports 02/21/21 White House working with Facebook, Twitter to tackle anti-vaxxers, Reuters says 02/21/21 Gates says social media bans not answer to divisiveness, Bloomberg reports 02/17/21 Twitter to start testing voice DMs, Android Central says TWTR Twitter $71.91 / -1.27 (-1.74%) 02/24/21 #SocialStocks: Snap shares advance following first investor day 02/22/21 Before the Move: Watch Snap ahead of first investor day meeting 02/17/21 #SocialStocks: TikTok parent to test waters under Biden administration 02/12/21 The Intersection: Crypto and Wall Street This Week 04/29/21 Twitter - TWTR 12:00 Today Twitter, Inc. TWTR Twitter $71.91 / -1.27 (-1.74%) 02/12/21 Twitter call volume above normal and directionally bullish 02/10/21 Early notable gainers among liquid option names on February 10th 02/10/21 Notable open interest changes for February 10th 02/09/21 Twitter options imply 20.7% move in share price post-earnings

Events

Earnings calls, analyst events, roadshows and more

DAO
Today at 06:00

Youdao - DAO Conference Calls
MOGU
Today at 06:30

Mogu - MOGU Conference Calls
NTES
Today at 07:00

NetEase - NTES Conference Calls
MNSO
Today at 07:00

Miniso - MNSO Conference Calls
SUBCY
Today at 07:00

Subsea 7 - SUBCY Conference Calls
Today at 07:00

Utilities Industry Meetings
LI
Today at 07:30

Li Auto - LI Conference Calls
VIPS
Today at 07:30

Vipshop - VIPS Conference Calls
AMRN
Today at 07:30

Amarin - AMRN Conference Calls
CNP
Today at 08:00

CenterPoint Energy - CNP Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	OUT X OUT Outfront Media Block Trade Managers: Morgan Stanley Priced at: $22.00 1.76M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BWAY X BWAY Brainsway Spot Secondary Managers: Oppenheimer Priced at: $8.50 4.62M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CCL X CCL Carnival Spot Secondary Managers: Goldman Sachs Priced at: $25.10 40.45M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PAVM X PAVM PAVmed Spot Secondary Managers: Cantor Fitzgerald Priced at: $4.60 9.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SHOP X SHOP Shopify Spot Secondary Managers: Citi, Credit Suisse & Goldman Sachs Priced at: $1,315 1.18M Shares
Tues	DISCK X DISCK Discovery Inc. Block Trade Managers: Credit Suisse Priced at: $42.70 11M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BCTX X BCTX BriaCell IPO Managers: ThinkEquity Priced at: $4.25 5.88M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BFRA X BFRA Biofrontera Secondary Managers: Benchmark, LAKE Priced at: $6.68 1.334M Shares FRPT X FRPT Freshpet Secondary Managers: BofA, Baird & Truist Priced at: $143.00 2.1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CELC X CELC Celcuity Spot Secondary Managers: Craig-Hallum Priced at: $14.00 1.714M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	SCR X SCR Score Media Secondary Managers: Morgan Stanley, Credit Suisse, Canaccord & Macquarie Priced at: $27.00 6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TROX X TROX Tronox Secondary Managers: JPMorgan, BofA, Deutsche Bank, Morgan Stanley Priced at: $18.25 19.11M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	ADMS X ADMS Adamas Pharmaceuticals Spot Secondary Managers: SVB Leerink, William Blair & JMP Securities $4.30-4.40 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial APAM X APAM Artisan Partners Spot Secondary Managers: BofA $49.38 1.11M Shares APEI X APEI American Public Education Spot Secondary Managers: Truist & William Blair $25.00-26.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial GPRE X GPRE Green Plains Spot Secondary Managers: Jefferies & BofA $23.00-24.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial IFRX X IFRX InflaRx Spot Secondary Managers: Guggenheim & Raymond James $4.75-5.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ITP X ITP IT Tech Packaging Spot Secondary Managers: Maxim $0.9901 RCEL X RCEL Avita Medical Spot Secondary Managers: Piper Sandler & Cowen $21.00-21.50 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	GTES X GTES Gates Industrial Secondary Managers: Citi & Evercore ISI, Barclays, Credit Suisse, Goldman Sachs, Morgan Stanley, RBC Capital, UBS, Baird, Nomura, Wells Fargo, Guggenheim, KeyBanc $17.87 22M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

View All Syndicate Announcements »

Gilead, Vir Biotechnology establish collaboration for chronic HBV

TODAY'S FREE FLY STORIES

Get Full Fly Access